Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward

Immunotherapy has revolutionized previous triple-negative breast cancer (TNBC) treatment algorithms, prompting researchers and clinicians to consider the expansion of the role of immunotherapy in other settings, including the earlier stage of the disease (e.g., as neoadjuvant and adjuvant therapy)....

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Cusmai, Antonio, Gadaleta-Caldarola, Gennaro, Palmiotti, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146481/
https://www.ncbi.nlm.nih.gov/pubmed/35630016
http://dx.doi.org/10.3390/medicina58050600
_version_ 1784716574153768960
author Rizzo, Alessandro
Cusmai, Antonio
Gadaleta-Caldarola, Gennaro
Palmiotti, Gennaro
author_facet Rizzo, Alessandro
Cusmai, Antonio
Gadaleta-Caldarola, Gennaro
Palmiotti, Gennaro
author_sort Rizzo, Alessandro
collection PubMed
description Immunotherapy has revolutionized previous triple-negative breast cancer (TNBC) treatment algorithms, prompting researchers and clinicians to consider the expansion of the role of immunotherapy in other settings, including the earlier stage of the disease (e.g., as neoadjuvant and adjuvant therapy). The role of chemoimmunotherapy have been assessed in some recently presented and published clinical trials, including the KEYNOTE-522, the IMpassion031, and the GeparNUEVO. In the current Editorial, we will provide a critical snapshot of these studies, exploring strengths and limitations of neoadjuvant chemotherapy in early TNBC.
format Online
Article
Text
id pubmed-9146481
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91464812022-05-29 Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward Rizzo, Alessandro Cusmai, Antonio Gadaleta-Caldarola, Gennaro Palmiotti, Gennaro Medicina (Kaunas) Commentary Immunotherapy has revolutionized previous triple-negative breast cancer (TNBC) treatment algorithms, prompting researchers and clinicians to consider the expansion of the role of immunotherapy in other settings, including the earlier stage of the disease (e.g., as neoadjuvant and adjuvant therapy). The role of chemoimmunotherapy have been assessed in some recently presented and published clinical trials, including the KEYNOTE-522, the IMpassion031, and the GeparNUEVO. In the current Editorial, we will provide a critical snapshot of these studies, exploring strengths and limitations of neoadjuvant chemotherapy in early TNBC. MDPI 2022-04-27 /pmc/articles/PMC9146481/ /pubmed/35630016 http://dx.doi.org/10.3390/medicina58050600 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Rizzo, Alessandro
Cusmai, Antonio
Gadaleta-Caldarola, Gennaro
Palmiotti, Gennaro
Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
title Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
title_full Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
title_fullStr Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
title_full_unstemmed Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
title_short Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
title_sort current and future role of neoadjuvant chemoimmunotherapy for early triple-negative breast cancer: which way to go forward
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146481/
https://www.ncbi.nlm.nih.gov/pubmed/35630016
http://dx.doi.org/10.3390/medicina58050600
work_keys_str_mv AT rizzoalessandro currentandfutureroleofneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcancerwhichwaytogoforward
AT cusmaiantonio currentandfutureroleofneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcancerwhichwaytogoforward
AT gadaletacaldarolagennaro currentandfutureroleofneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcancerwhichwaytogoforward
AT palmiottigennaro currentandfutureroleofneoadjuvantchemoimmunotherapyforearlytriplenegativebreastcancerwhichwaytogoforward

Ejemplares similares